Basket cover image
19 handpicked stocks

Resilient Sportswear Plays Beyond The Tariff

Following Puma's significant profit warning due to U.S. tariffs, an investment opportunity emerges in the sportswear sector. This theme focuses on athletic apparel companies with resilient supply chains and less exposure to the trade policies impacting global brands.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+9

Author avatar

Han Tan | Market Analyst

Updated 3 days ago | Published at juillet 25

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

LULU

Lululemon Athletica Inc.

LULU

Current price

$197.66

Premium athletic apparel company with strong brand positioning and supply chain diversification strategies.

NKE

Nike, Inc.

NKE

Current price

$76.88

Global athletic footwear and apparel leader with established supply chain management capabilities.

UAA

Under Armour, Inc.

UAA

Current price

$5.08

Performance athletic wear company with focus on innovation and supply chain optimization.

About This Group of Stocks

1

Our Expert Thinking

Following Puma's profit warning due to U.S. tariffs, we identified a tactical opportunity in the sportswear sector. Companies with diversified or localized supply chains may demonstrate greater financial stability and potentially capture market share from more exposed competitors during this period of trade policy uncertainty.

2

What You Need to Know

This group focuses on athletic apparel and footwear companies that appear better positioned to navigate trade policy challenges. These stocks represent a tactical play on supply chain resilience, offering potential exposure to a sector-wide re-evaluation of manufacturing dependencies and market positioning.

3

Why These Stocks

Each company was handpicked by professional analysts based on their supply chain diversification and reduced exposure to U.S. tariffs on Asian imports. This curated selection aims to capitalize on near-term market dislocations while targeting firms that could benefit from competitors' vulnerabilities.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+39.70%

Group Performance Snapshot

39.7%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 39.7% over the next year.

12 of 19

Stocks Rated Buy by Analysts

12 of 19 assets in this group are rated Buy by professional analysts.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

Supply Chain Advantage

While competitors struggle with tariff impacts, these companies have built more resilient manufacturing networks. This positioning could translate into competitive advantages and market share gains.

📈

Sector Disruption Opportunity

Puma's profit warning signals broader industry vulnerabilities that could reshape the sportswear landscape. Companies with stronger supply chain strategies may emerge as clear winners.

🎯

Tactical Market Play

This theme captures a specific moment of market dislocation in the athletic apparel sector. Professional analysts selected these stocks to capitalize on near-term competitive shifts and supply chain re-evaluation.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

The New Cost of Compliance: Investing in HR Tech

The New Cost of Compliance: Investing in HR Tech

Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.

View stocks
GLP-1s Target Liver Disease

GLP-1s Target Liver Disease

The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.

View stocks
Pharma's Digital Prescription

Pharma's Digital Prescription

Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.

View stocks
View all Stock Groups

Frequently Asked Questions

Everything you need to know about the product and billing.